(CercleFinance.com) – Genfit publishes a net loss of 23.7 million euros and an operating loss of 27.3 million for 2022, compared to profits of 67.3 and 31.8 million respectively. euros earned the previous year.
The biopharmaceutical company’s operating income contracted to 26.6 million euros, compared to 85.6 million in 2021. The turnover, of 20.2 million euros, mainly comes from three related flows at Ipsen.
As of December 31, 2022, cash, cash equivalents and other current financial assets amounted to €140.6 million, compared to €258.8 million at the end of 2021, but ‘capable of financing operations until the third quarter 2024’.